Advertisement

Indikationen für plasmatische Hämoderivate

  • W. Muntean
Conference paper
  • 9 Downloads

Zusammenfassung

Die großen Fortschritte bei der Bereitstellung einer großen Zahl unterschiedlicher Blutkomponenten durch die transfusionsmedizinischen Dienste verlangen auch vom behandelnden Arzt eine genaue Kenntnis nicht nur der Wirkungen, sondern auch der Nebenwirkungen und potentiellen Risken der einzelnen Blutkomponenten. Eine ungezielte „breite“ Anwendung von Blutkomponenten ist nicht nur wenig effektiv, sondern erhöht auch das Risiko durch die Blutkomponententherapie. Die Richtlinien einer modernen Blutkomponententherapie verlangen unter einer gesicherte Indikation nach Abwägen des zu erwartenden Nutzens gegen das mögliche Risiko die Anwendung einer möglichst spezifischen Blutkomponente. Zwei Beispiele sollen Nutzen und Risken demonstrieren:

Literatur

  1. Auberger K (1992) Evaluation of a new protein-C concentrate and comparison of protein-C assays in a child with congenital protein-C deficiency. Ann Hematol 64: 146PubMedCrossRefGoogle Scholar
  2. Baudo F, DeGasperi A, Cataldo F, Caimi TM, Cattaneo D, Redaelli R, Pannacciulli E, Corti A, Mazza E, Belli L (1992) Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thromb Res 68: 409PubMedCrossRefGoogle Scholar
  3. Blatt PM, Kingdon HS, McLean G, Roberts HR (1974) Thrombogenic material in prothrombin complex concentrates. Ann Intern Med 81: 766PubMedGoogle Scholar
  4. Blauhut B, Kramar H, Vinazzer H, Bergmann H(1985) Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 39: 81Google Scholar
  5. Brackmann HH, Egli H (1981) Treatment of haemophilia patients with inhibitors. In: Seligsohn U, Rimon A, Horoszowski H (eds) Haemophilia. Castle House Publications, Kent, p 113Google Scholar
  6. Brettler DB (1993) Are pure concentrates better? Hemophilia world 8: 4Google Scholar
  7. De Stefano V, Triolo L, De Martini D, Ferrelli R, Mori R, Leone G (1987) Antithrombin III loss in patients with nephrotic syndrome or receiving continuous ambulatory peritoneal dialysis. Evidence of inactive antithrombin III in urine of patients with nephrotic syndrome. J Lab Clin Med 109: 550PubMedGoogle Scholar
  8. Dickneite G, Paques EP (1993) Reduction of mortality with antithrom-bin III in septicemic rats: a study of klebsiella pneumoniae induced sepsis. Thromb Haemostas 69: 9Google Scholar
  9. Dreyfus M, Magny JF, Bridey F, Schwarz HP, Planche C, Dehan M, Tchernia G (1991) Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl j Med 325: 1565PubMedCrossRefGoogle Scholar
  10. Flaherty Mj,Henderson R, Wener MH, (1989) latrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery. Ann Intern Med 111: 631Google Scholar
  11. Goldsmith JAM, Deutsche J, Tang M, Green D (l991) CD4 cells in HIV- 1 infected hemophiliacs: effect of factor VIII concentrates. Thromb Haemostas 66:41Google Scholar
  12. Hedner U,Kisler W (1993) Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 71: 1836CrossRefGoogle Scholar
  13. Hellgren M,Tenborn L, Abildgaard U (1982) Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin Gynecol Obstet Invest 14: 127Google Scholar
  14. Hilgartner MW, Knatterud GL and the FEIBA Study Group (1992) The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 61: 36Google Scholar
  15. Hultin MB(I979) Activated clotting factors in factor IX concentrates. Blood 54: 1028Google Scholar
  16. Kario K, Matsuo T,Kodama K, Matsuo M (1992) Prophylactic antithrombin III administration during pregnancy immediately reduces the thrombin hyperactivity of congenital antithrombin III deficiency by forming thrombin-antithrombin III complexes. Thromb Res 66: 509Google Scholar
  17. Keiling A, Holst F, Seitz R, Wallin R, Saldeen T,(l991)Severe factor XIII deficiency in disturbances of synthesis or increased consumption (DZC).Treatment of bleeding complications by factor XIII concentrates Thromb Haemostos 65: 1237Google Scholar
  18. Kingdon HS, Lundblad RL, Veltkamp JJ, Aronson DL(1975) Potentially thrombogenic materials in factor IX concentrates. Thromb Diath Haemorth 33: 61Google Scholar
  19. Laursen B,Mortensen JZ, Frost L, Hansen KB(1981) Disseminated intra vascular Coagulation in hepatic failure treated with antithrombin III. Thromb Res 22: 70Google Scholar
  20. Leone G,Gugliotta L, Mazzucconi MG, De Stefano V, Belmonte MM, Dragoni, F, Specchia G, Centra A,Gamba G, Camera A,Mandelli F, (1993) Evidence of hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E coliL–Asparaginase: a GIMEMA study. Thromb Haemostas 69: 12Google Scholar
  21. MacGregor IR, Ferguson JM, McLaughlin LF, Burnouf T, Prowse CV (1991)Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in canine model of thrombogenicity.Thromb Haemostas 66: 809Google Scholar
  22. Maki M,TeraoT, Ikenoue T, Takemura T, Sekiba,Shirakawa K, Soma H (1987) Clinical evaluation of antithrombin III concentrate (BI 6.OI3) for disseminated intravascular coagulation in obstetrics. Gynecol Obstet Invest 23: 230–240CrossRefGoogle Scholar
  23. Makris M, Kitchen S, Russell F, Preston FE (1991) Clinical use and monitoring of activated recombinant factor FVII concenkate (rFVIIa) in haemophilia A patients with factor VIII inhibitors. Thromb Haemostas 65: 64Google Scholar
  24. Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Bottasso B, Simoni L, Rosenberg RD (1990) Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood 76: 254Google Scholar
  25. Mannucci PM, Gringeri A, de Biasi R, Baudo F, Morfini M, Ciavarella N (1992) Immune status of asymptomatic HIV-infected hemophiliacs: randomized, prospective, two-year comparison of treatment with a high-purity or an intermediate-purity factor VIII concentrate. Thromb Haemostas 67: 310Google Scholar
  26. Marassi A, Manzullo V, di Carlo V, Mannucci PM (1978) Thromboem-bolism following prothrombin complex concentrates and major surgery in liver disease. Thromb Haemostas 39: 787Google Scholar
  27. Menache D, O’Malley JP, Schorr JB, Wagner B, Williams C, the Cooperative Study Group (1990) Evaluation of the safety, recovery, halflife, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Blood 75: 33Google Scholar
  28. Muntean W, Finding K, Gamillscheg A, Zenz W (1992) Multiple thromboses and coumarin-induced skin necrosis in a young child with antiphospholipid antibodies. Thromb Haemorrh Disord 5: 43Google Scholar
  29. Muntean W, Finding K, Gamillscheg A, Zenz W (1992) Multiple thromboses and coumarin-induced skin necrosis in a young child with antiphospholipid antibodies. Thromb Haemorrh Disord 5: 43Google Scholar
  30. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER (1988) Thrombolytic therapy with tissue plasminogen activator or skeptokinase induces transient thrombin activity. Blood 72: 616PubMedGoogle Scholar
  31. Rake MO, Pannell G, Flute PT, Williams R (1970) Inkavascular coagulation in acute hepatic necrosis. Lancet i: 533Google Scholar
  32. Rousou J, Levitsky S, Gonzalez-Lavin L, Cosgrove D, Magilligan D, Weldon C, Hiebert C, Hess P, Joyce L, Bergsland J, Gazzangia A (1989) Randomized clinical trial of fibrin sealant in patients undergoing resternotomy or cardiac operations. J Thor Cardiovasc Surg 97: 2Google Scholar
  33. Smid WM, vdMeer T, Smit JW, Halie MR (1993) The course of preexistent immune abnormalities in HIV negative haemophiliacs keated for two years with a monoclonal purified factor VIII concentrate. Thromb Haemostas 69: 306Google Scholar
  34. Schulman S, Tengborn L (1992) Treatment of venous thromboembolism in patients with congenital deficiency of antithrombin III. Thromb Haemostas 68: 634Google Scholar
  35. Schwartz RS, Bauer KA, Rosenberg RD (1989) Clinical experience with antithrombin III concentrate in keatment of congenital and acquired deficiency of antithrombin. Am j Med 87 [Suppl 3 B]: 53CrossRefGoogle Scholar
  36. Stricken RB, Lane PK, Leffert JD, Rodgers GM, Shaman MA, Corash L (1988) Development of antithrombin antibodies following surgery in patients with prosthetic cardiac valves. Blood 72: 1375Google Scholar
  37. Vinazzer H (1989) Therapeutic use of antithrombin III in shock and disseminated intraavascular coagulation. Semin Thromb Hemostas 15: 347CrossRefGoogle Scholar
  38. Zaunschirm A, Muntean W (1986) Correction of hemostatic imbalances induced by L-Asparaginase therapy in children with acute lymphoblastic leukemia. Ped Hematol Oncol 3: 19CrossRefGoogle Scholar
  39. Zehnder JL, Leung LLK (1990) Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 76: 2011PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1997

Authors and Affiliations

  • W. Muntean
    • 1
    • 2
  1. 1.Universitätsklinik für Kinder- und JugendheilkundeGrazÖsterreich
  2. 2.Universitätsklinik für Kinder- und JugendheilkundeGrazÖsterreich

Personalised recommendations